Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million.
Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
Women held 29% of biotech board seats in fiscal 2025 but just 8.8% of CEO roles, highlighting uneven progress across industry leadership spots.
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events.
Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks.
Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago.
Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.